Royalty Pharma reports third quarter 2026 results

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.¹

The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No. Description

99.1 Press release issued by Royalty Pharma plc, dated November 4, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROYALTY PHARMA PLC

Date: November 4, 2026 By: /s/ Terrance Coyne

Terrance Coyne

Chief Financial Officer

Press Release

November 4, 2026

R oyalty Pharma reports third quarter 2026 results

Portfolio Rece ipts growth o f 9% to $890 million ; Royalty Receipts growth of 9%²

Net cash provided by operating activities of $686 million³

Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million⁴

NEW YORK, NY, November 4, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.

"Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board. "We delivered⁵ 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date⁵. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter⁶. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines' Rasonque and Teva's Weltruza and positive Phase 3 results for Amgen's Imdelltra. Lastly, we remain excited by the potential for R&D co-funding with global biopharma - where we have announced $1 billion of transactions so far this year - which represents an important new opportunity for our business. Looking ahead, with a robust deal pipeline and strong fundamenta